Clinical trial
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet…
NCT00269893 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00269893 |
|---|---|
| Title | A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty |
| Official title | A Phase III Double-Blind, Placebo-Controlled Multicenter Study of Abciximab In Patients Undergoing High Risk Coronary Angioplasty (EPIC) |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary |
| Intervention type | Drug |
| Interventions | Abciximab, Placebo |
| Enrollment | 2,038 |
| Start date | Nov 1, 1991 |
| Primary completion | Nov 1, 1992 |
| Completion | Nov 1, 1992 |
| First posted | Dec 26, 2005 |
| Last update posted | Jun 2, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: